Lixisenatide (Adlyxin)

Overview

Lixisenatide is a once-daily GLP-1 receptor agonist developed by Sanofi and marketed as Adlyxin in the United States and as Lyxumia internationally. It belongs to the incretin class of therapies and is structurally derived from exendin-4, a peptide first identified in Gila monster venom.

It is often described as a “prandial” or mealtime GLP-1 agonist. Rather than aiming for continuous 24-hour receptor activation, it is studied for its pronounced, short-lived action around meals, where it works to blunt the rise in blood sugar that follows eating.

Lixisenatide received FDA approval in 2016 for type 2 diabetes as an adjunct to diet and exercise. Sanofi discontinued its U.S. marketing in 2023 for commercial reasons rather than safety concerns, and it remains available in a number of other countries.

How it works

Like other GLP-1 receptor agonists, lixisenatide is reported to increase glucose-dependent insulin release, reduce glucagon secretion, and slow gastric emptying. Its comparatively short duration of action is thought to concentrate these effects around mealtimes, which is why it is commonly associated with control of post-meal (postprandial) glucose rather than fasting glucose.

A distinguishing feature discussed in the literature is its marked slowing of gastric emptying. Preclinical work suggests this effect does not appear to diminish with repeated dosing (tachyphylaxis) the way it can with some longer-acting agents, and it has been proposed as a major contributor to its effect on post-meal glucose excursions.

Reported benefits

• Studied for improved control of post-meal blood-sugar spikes in type 2 diabetes
• Reported reductions in HbA1c when used with diet and exercise or alongside basal insulin
• Pronounced slowing of gastric emptying, studied as its primary prandial mechanism
• Cardiovascular safety observed in a large outcomes trial (ELIXA) in people with recent acute coronary syndrome

These are reported and studied effects in a diabetes context, not guaranteed outcomes, and much of the weight-related interest in GLP-1 agonists comes from other agents in the class.

Considerations & side effects

The most commonly reported side effects are gastrointestinal, including transient nausea, vomiting, and diarrhea, which are generally mild to moderate and tend to ease over time. Because it can lower blood sugar, hypoglycemia is also possible, particularly when combined with insulin or sulfonylureas.

As with other GLP-1 receptor agonists, considerations discussed in labeling and reviews include gastrointestinal tolerability, the potential for injection-site reactions, and caution in people with a history of pancreatitis or severe gastrointestinal disease. It is intended for use under medical supervision and is not a substitute for evaluation and treatment by a qualified clinician.